Genelux Corporation Common Stock (GNLX) is a publicly traded Healthcare sector company. As of May 21, 2026, GNLX trades at $2.93 with a market cap of $127.80M and a P/E ratio of -3.41. GNLX moved +4.46% today. Year to date, GNLX is -15.80%; over the trailing twelve months it is +6.55%. Its 52-week range spans $1.99 to $8.54. Analyst consensus is strong buy with an average price target of $19.75. Rallies surfaces GNLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Genelux Reports $26.3M Cash Runway into Q1 2027 and Advances Olvi-Vec Trials: Genelux closed Q1 with $26.3M cash, funding into Q1 2027, while R&D expenses rose by $1.1M to $5.8M. It confirmed Phase 3 OnPrime/GOG-3076 ovarian trial topline data in 2H26 and reported 33% response rate in Phase 1b/2 SCLC and 60% disease control in Phase 2 NSCLC.
| Metric | Value |
|---|---|
| Price | $2.93 |
| Market Cap | $127.80M |
| P/E Ratio | -3.41 |
| EPS | $-0.85 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.54 |
| 52-Week Low | $1.99 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $8.00K |
| Net Income | $-33.58M |
| Gross Margin | 0.00% |
4 analysts cover GNLX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.75.